Cargando…

Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors

Prexasertib is a novel inhibitor of checkpoint kinase 1. The primary objective of this study was to evaluate prexasertib tolerability in Japanese patients with advanced solid tumors. This nonrandomized single‐arm open‐label phase 1 study of prexasertib consisted of 2 dose levels, 80 mg/m(2) and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwasa, Satoru, Yamamoto, Noboru, Shitara, Kohei, Tamura, Kenji, Matsubara, Nobuaki, Tajimi, Masaomi, Lin, Aimee B., Asou, Hiroya, Cai, Zhihong, Inoue, Koichi, Shibasaki, Yuko, Saito, Kanako, Takai, Hiroki, Doi, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247064/ https://www.ncbi.nlm.nih.gov/pubmed/30040168 http://dx.doi.org/10.1111/cas.13750

Ejemplares similares

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2020)

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2020)

Automated synthesis of prexasertib and derivatives enabled by continuous-flow solid-phase synthesis
por: Liu, Chenguang, et al.
Publicado: (2021)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis
por: Doi, Toshihiko, et al.
Publicado: (2017)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
por: Blosser, Wayne D., et al.
Publicado: (2020)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database
por: Rai, Shinya, et al.
Publicado: (2022)

Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
por: Heidler, Christopher L., et al.
Publicado: (2019)

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
por: Brill, Ethan, et al.
Publicado: (2017)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
por: Lee, Jung-Min, et al.
Publicado: (2018)

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2018)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials
por: Tanabe, Yuko, et al.
Publicado: (2016)

Cardiovascular events after the initiation of immune checkpoint inhibitors
por: Suzuki, Yuta, et al.
Publicado: (2023)

Synthesis, Crystal Structure, and Photoluminescent Properties of 3,3′,4,4′-Tetraethyl-5,5′-divinyl-2,2′-bipyrrole Derivatives
por: Okawara, Toru, et al.
Publicado: (2017)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
por: Tada, Yasuko, et al.
Publicado: (2018)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
por: Kawazoe, Akihito, et al.
Publicado: (2020)

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Selective synthesis of substituted amino-quinoline derivatives by C-H activation and fluorescence evaluation of their lipophilicity-responsive properties
por: Fuchi, Yasufumi, et al.
Publicado: (2019)

Comparison between turbo spin-echo and echo planar diffusion-weighted imaging of the female pelvis with 3T MRI
por: Yoshizako, Takeshi, et al.
Publicado: (2021)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nopctp15tceeuvmj0k6rjn1s8f